Table 3 Treatment-related adverse effects of all grades
Categories | Any grade | Grades 1 and 2 | Grade 3 or higher |
|---|---|---|---|
Aspartate aminotransferase increased | 25 (100.0%) | 14 (56.0%) | 11 (44.0%) |
Alanine aminotransferase increased | 22 (88.0%) | 15 (60.0%) | 7 (28.0%) |
Hypoalbuminemia | 22 (88.0%) | 22 (88.0%) | 0 (0.0%) |
Neutrophil count decreased | 11 (44.0%) | 9 (36.0%) | 2 (8.0%) |
Lymphocyte count decreased | 24 (96.0%) | 11 (44.0%) | 13 (52.0%) |
Anemia | 20 (80.0%) | 17 (68.0%) | 3 (12.0%) |
Platelet count decreased | 15 (60.0%) | 10 (40.0%) | 5 (20.0%) |
Blood bilirubin increased | 18 (72.0%) | 13 (52.0%) | 5 (20.0%) |
Proteinuria | 9 (36.0%) | 9 (36.0%) | 0 (0.0%) |
Abdominal pain | 7 (28.0%) | 7 (28.0%) | 0 (0.0%) |
White blood cell decreased | 10 (40.0%) | 6 (24.0%) | (16.0%) |
Anorexia | 8 (32.0%) | 8 (32.0%) | 0 (0.0) |
Hyperglycemia | 15 (60.0%) | 15 (60.0%) | 0 (0.0%) |
Hyperuricemia | 11 (44.0%) | 11 (44.0%) | 0 (0.0%) |
Hypokalemia | 10 (40.0%) | 10 (40.0%) | 0 (0.0%) |
Rash | 1 (4.0) | 1 (4.0) | 0 (0.0) |
Hypertension | 6 (24.0%) | 5 (20.0%) | 1 (4.0%) |
Hand-foot syndrome | 14 (56.0%) | 13 (56.0%) | 0 (0.0) |
RCCEP | 1 (4.0%) | 1 (4.0%) | 0 (0.0%) |
Diarrhea | 2 (8.0%) | 2 (8.0%) | 0 (0.0%) |
Vomiting | 2 (8.0%) | 2 (8.0%) | 0 (0.0%) |
Fatigue | 14 (56.0%) | 14 (56.0%) | 0 (0.0%) |
Hematuria | |||
 Upper respiratory infection | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
 Gingival hemorrhage | 5 (20.0%) | 5 (20.0%) | 0 (0.0%) |
 Fever | 6 (24.0%) | 6 (24.0%) | 0 (0.0%) |
 Oral mucositis | 5 (20.0%) | 5 (20.0%) | 0 (0.0%) |
 Gingivitis | 5 (20.0%) | 5 (20.0%) | 0 (0.0%) |
 Ascites | 4 (16.0%) | 0 (0.0%) | 0 (0.0%) |
 Epistaxis | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
 Cough | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |
 Headache | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) |